Company Overview of DermTech, Inc.
DermTech International, a molecular diagnostic company, is engaged in developing and marketing gene expression tests to facilitate the diagnosis of dermatologic conditions. The company offers Adhesive Skin Sample Collection Kit, which consists of adhesive patches, instructions for use, a marking pen for lesion outlining, and a pre-addressed and prepaid return shipping pack. Its Adhesive Skin Sample Collection Kit allows for the collection of skin samples with minimal patient discomfort. The company also provides Pigmented Lesion Assay for reducing unnecessary surgical biopsy procedures and enhancing diagnostic accuracy; ribonucleic acid extraction services; and a smart phone based photoinfor...
11099 North Torrey Pines Road
La Jolla, CA 92037
Founded in 1995
Key Executives for DermTech, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer, Principal Financial & Accounting Officer, Secretary and Treasurer
Director of Business Administration
Compensation as of Fiscal Year 2015.
DermTech, Inc. Key Developments
DermTech, Inc. Presents at Emerging Medical Technologies Summit, Oct-20-2015 04:25 PM
Oct 7 15
DermTech, Inc. Presents at Emerging Medical Technologies Summit, Oct-20-2015 04:25 PM. Venue: Sofitel Hotel San Francisco, 223 Twin Dolphin Dr., Redwood City, CA 94065, United States.
U.S. Patent Office Grants DermTech, Inc.'s Broad Patent for Skin Cancer Gene Classifier
Apr 9 15
DermTech, Inc. announced that it has been issued a notice of allowance by the U.S. Patent Office for claims related to a gene classifier for pigmented skin lesion assessment. The gene classifier has been shown to be associated with melanoma skin cancer and can be used by clinicians to evaluate pigmented skin lesions. When used with the Adhesive Skin Sample Collection Kit, it provides a non-invasive measurement of melanoma related gene expression thereby facilitating accurate clinical diagnosis and helping avoid unnecessary surgical biopsies.
DermTech International Adds Three Members to its Commercialization Team
Jul 8 14
DermTech International announced that it has added three members to its commercialization team. Art Wampole will lead the company's sales effort, Annie Bell will lead the company's marketing strategy, and Mildred Romero will lead the company's reimbursement implementation. Art Wampole was previously the Vice President of Sales at Dermpath Diagnostics. Annie Bell held senior management positions in Sales and Marketing for Ameripath Inc. and was the general manager of Dermpath Diagnostics. Mildred Romero has held senior management positions and led reimbursement development at several innovative diagnostics companies including DexCom Inc. and Pathway Genomics Corporation.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 31, 2015
April 1, 2015
Most Searched Private Companies
Sponsored Financial Commentaries